{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:22:48Z","timestamp":1790947368895,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-025-05246-7","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T10:50:05Z","timestamp":1754391005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting MET and KRAS G12C co-occurring mutation in metastatic adenoid cystic carcinoma of the trachea: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Ling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youxin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keke","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"5246_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/0002-9610(74)90265-7","volume":"128","author":"RH Spiro","year":"1974","unstructured":"Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma of salivary origin a clinicopathologic study of 242 cases. Am J Surg. 1974;128:513\u201320.","journal-title":"Am J Surg"},{"key":"5246_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0003-4975(10)63653-3","volume":"26","author":"HC Grillo","year":"1978","unstructured":"Grillo HC. Tracheal tumors: surgical management. Ann Thorac Surg. 1978;26:112\u201325. https:\/\/doi.org\/10.1016\/S0003-4975(10)63653-3.","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"5246_CR3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/S0022-5223(96)70011-9","volume":"112","author":"DE Maziak","year":"1996","unstructured":"Maziak DE, Todd TRJ, Keshavjee SH, Winton TL, Van Nostrand P, Griffith Pearson F. Adenoid cystic carcinoma of the airway: thirty-two-year experience. J Thorac Cardiovasc Surg. 1996;112(6):1522\u201332. https:\/\/doi.org\/10.1016\/S0022-5223(96)70011-9.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"5246_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/9781118468791.ch17","volume-title":"Lung cancer","author":"F Sammartino","year":"2014","unstructured":"Sammartino F, Macchiarini P. Primary tracheal tumors. In: Roth JA, Hong WK, Komaki RU, Tsao AS, Chang JY, Blackmon SH, editors. Lung cancer. Wiley; 2014. p. 267\u201377. https:\/\/doi.org\/10.1002\/9781118468791.ch17."},{"key":"5246_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.ejcts.2010.08.047","volume":"39","author":"MB Shadmehr","year":"2011","unstructured":"Shadmehr MB, Farzanegan R, Graili P, Javaherzadeh M, Arab M, Pejhan S, Karam MB, Abbasidezfouli A. Primary major airway tumors; management and results. Eur J Cardio-Thoracic Surg. 2011;39:749\u201354. https:\/\/doi.org\/10.1016\/j.ejcts.2010.08.047.","journal-title":"Eur J Cardio-Thoracic Surg"},{"key":"5246_CR6","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2014.19.32.4878","author":"M ElMarjany","year":"2014","unstructured":"ElMarjany M, Arsalane A, Sifat H, Andaloussi K, Oukabli M, Hadadi K, Kabiri EH, Mansouri H. Primary adenoid cystic carcinoma of the trachea: a report of two cases and literature review. Pan Afr Med J. 2014. https:\/\/doi.org\/10.11604\/pamj.2014.19.32.4878.","journal-title":"Pan Afr Med J"},{"key":"5246_CR7","first-page":"7527","volume":"7","author":"Z Huo","year":"2014","unstructured":"Huo Z, Meng Y, Wu H, Shen J, Bi Y, Luo Y, Cao J, Liang Z. Adenoid cystic carcinoma of the tracheobronchial tree: clinicopathologic and immunohistochemical studies of 21 cases. Int J Clin Exp Pathol. 2014;7:7527\u201335.","journal-title":"Int J Clin Exp Pathol"},{"key":"5246_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S1470","volume":"12","author":"SA Laurie","year":"2011","unstructured":"Laurie SA, Ho AL, Fury MG, Sherman E, Pfi DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet. 2011;12:815. https:\/\/doi.org\/10.1016\/S1470.","journal-title":"Lancet"},{"key":"5246_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188523","author":"J Nightingale","year":"2021","unstructured":"Nightingale J, Lum B, Ladwa R, Simpson F, Panizza B. Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy. Biochim Biophys Acta Rev Cancer. 2021. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188523.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"5246_CR10","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.2147\/CMAR.S282617","volume":"13","author":"Y Liu","year":"2021","unstructured":"Liu Y, Li H, Zhu J, Zhang Y, Liu X, Li R, Zhang Q, Cheng Y. The prevalence and concurrent pathogenic mutations of krasg12c in northeast Chinese non-small-cell lung cancer patients. Cancer Manag Res. 2021;13:2447\u201354. https:\/\/doi.org\/10.2147\/CMAR.S282617.","journal-title":"Cancer Manag Res"},{"key":"5246_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153036","volume":"216","author":"Y Ma","year":"2020","unstructured":"Ma Y, Du Y, Wang R, Ji X, Wu J, Liu Y, Guo X, Zhang Y. Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens. Pathol Res Pract. 2020;216: 153036. https:\/\/doi.org\/10.1016\/j.prp.2020.153036.","journal-title":"Pathol Res Pract"},{"key":"5246_CR12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/nejmoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang Y-J, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207\u201317. https:\/\/doi.org\/10.1056\/nejmoa1917239.","journal-title":"N Engl J Med"},{"key":"5246_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02752","author":"S-HI Ou","year":"2022","unstructured":"Ou S-HI, J\u00e4nne PA, Leal TA, Rybkin II, Sabari JK, Barve MA, Bazhenova L, Johnson ML, Velastegui KL, Cilliers C, Christensen JG, Yan X, Chao RC, Papadopoulos KP. First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS G12C solid tumors (KRYSTAL-1). J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/jco.21.02752.","journal-title":"J Clin Oncol"},{"key":"5246_CR14","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7150\/jca.49391","volume":"12","author":"T Cheng","year":"2020","unstructured":"Cheng T, Gu Z, Song D, Liu S, Tong X, Wu X, Lin Z, Hong W. Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib. J Cancer. 2020;12:640\u201351. https:\/\/doi.org\/10.7150\/jca.49391.","journal-title":"J Cancer"},{"key":"5246_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0856","author":"S Suzuki","year":"2021","unstructured":"Suzuki S, Yonesaka K, Teramura T, Takehara T, Kato R, Sakai H, Haratani K, Tanizaki J, Kawakami H, Hayashi H, Sakai K, Nishio K, Nakagawa K. KRAS inhibitor-resistance in MET-amplified KRASG12C non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms. Clin Cancer Res. 2021. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0856.","journal-title":"Clin Cancer Res"},{"key":"5246_CR16","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior IA, Lewis PD, Mattos C. A comprehensive survey of RAS mutations in cancer. Cancer Res. 2012;72:2457\u201367. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2612.","journal-title":"Cancer Res"},{"key":"5246_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102070","author":"D Uprety","year":"2020","unstructured":"Uprety D, Adjei AA. KRAS: from undruggable to a druggable cancer target. Cancer Treat Rev. 2020. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102070.","journal-title":"Cancer Treat Rev"},{"key":"5246_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/13543784.2018.1462336","volume":"27","author":"G Pasquini","year":"2018","unstructured":"Pasquini G, Giaccone G. C-MET inhibitors for advanced non-small cell lung cancer. Expert Opin Investig Drugs. 2018;27:363\u201375. https:\/\/doi.org\/10.1080\/13543784.2018.1462336.","journal-title":"Expert Opin Investig Drugs"},{"key":"5246_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2018.07.006","volume":"123","author":"HG Vuong","year":"2018","unstructured":"Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer\u2014A systematic review and meta-analysis. Lung Cancer. 2018;123:76\u201382. https:\/\/doi.org\/10.1016\/j.lungcan.2018.07.006.","journal-title":"Lung Cancer"},{"key":"5246_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1073\/pnas.98.1.247","volume":"98","author":"GH Xiao","year":"2001","unstructured":"Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, VandeWoude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor\/Met via the phosphatidylinositol 3-kinase\/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA. 2001;98:247\u201352. https:\/\/doi.org\/10.1073\/pnas.98.1.247.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5246_CR21","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/cncr.29986","volume":"122","author":"G Borthakur","year":"2016","unstructured":"Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016;122:1871\u20139. https:\/\/doi.org\/10.1002\/cncr.29986.","journal-title":"Cancer"},{"key":"5246_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1158\/1078-0432.CCR-19-1667","volume":"26","author":"JK Rotow","year":"2020","unstructured":"Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, FecedelaCruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, RossCamidge D, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. Co-occurring alterations in the RAS\u2013MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer. Clin Cancer Res. 2020;26:439\u201349. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1667.","journal-title":"Clin Cancer Res"},{"key":"5246_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11060-020-03592-8","volume":"149","author":"N Manoharan","year":"2020","unstructured":"Manoharan N, Choi J, Chordas C, Zimmerman MA, Scully J, Clymer J, Filbin M, Ullrich NJ, Bandopadhayay P, Chi SN, Yeo KK. Trametinib for the treatment of recurrent\/progressive pediatric low-grade glioma. J Neurooncol. 2020;149:253\u201362. https:\/\/doi.org\/10.1007\/s11060-020-03592-8.","journal-title":"J Neurooncol"},{"key":"5246_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cca.2017.07.012","volume":"472","author":"M Rousset","year":"2017","unstructured":"Rousset M, Dutriaux C, Bosco-L\u00e9vy P, Prey S, Pham-Ledard A, Dousset L, G\u00e9rard E, Bouchet S, Canal-Raffin M, Titier K, Molimard M. Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma. Clin Chim Acta. 2017;472:26\u20139. https:\/\/doi.org\/10.1016\/j.cca.2017.07.012.","journal-title":"Clin Chim Acta"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05246-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05246-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05246-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:48:13Z","timestamp":1757357293000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05246-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5246"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05246-7","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declared there was no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"389"}}